{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:37:59Z","timestamp":1793147879949,"version":"4.5.0"},"reference-count":109,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Head and neck squamous cell carcinoma (HNSCC) is among the top 10 most common cancer entities worldwide. For patients with locally advanced, non-metastatic HNSCC, the standard of care treatment often includes concomitant chemoradiotherapy with cisplatin. However, a considerable number of these patients are cisplatin-ineligible. To inform treatment selection for cisplatin-unfit patients undergoing radiotherapy (RT) for HNSCC, a network meta-analysis was performed. Method: In November 2023 a systematic search was conducted and updated in January 2026 searching four electronic databases (Medline, Web of Science, Cochrane Library, and Scopus) to identify randomized controlled trials (RCTs) analyzing overall survival (OS), progression-free survival (PFS), locoregional control (LC) and adverse events (AE) of RT combined with chemo-\/immunotherapy with relevance to treatment selection in cisplatin-ineligible patients with HNSCC. Results: From all (15,551) search results, 52 publications concerning 28 RCTs reporting on approximately 7000 patients were included. The therapeutic concepts in the experimental group included all combinations of RT with concurrent systemic therapy, excluding cisplatin-based regimens, and were compared with any control treatment. All studies had sufficient quality for inclusion. None of the systemic agents showed a significant improvement in OS, PFS, or LC compared to cisplatin. Carboplatin + 5-FU and mitomycin C + 5-FU improved LC compared to hyperfractionated accelerated radiotherapy (HART). Compared to cisplatin, durvalumab and cetuximab were associated with less dysphagia, cetuximab with less renal impairment, and panitumumab and cetuximab with less weight loss. Conclusions: Carboplatin + 5-FU and Mitomycin C + 5-FU achieve superior LC compared to HART. Targeted therapy and immunotherapy were associated with less severe AEs.<\/jats:p>","DOI":"10.3390\/cancers18101599","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:04:09Z","timestamp":1778763849000},"page":"1599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-Cisplatin Concurrent Systemic Therapy with Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Network Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.3390","volume":"18","author":[{"given":"Katharina Sophie","family":"Sch\u00f6bel","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Josephin","family":"Schoele","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-9862","authenticated-orcid":false,"given":"Georg","family":"Wurschi","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8085-8455","authenticated-orcid":false,"given":"Klaus","family":"Pietschmann","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-4699","authenticated-orcid":false,"given":"Maximilian","family":"R\u00f6mer","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s00761-019-0534-0","article-title":"Epidemiologie von Kopf-Hals-Tumoren in Deutschland","volume":"25","author":"Wienecke","year":"2019","journal-title":"Onkologie"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105042","DOI":"10.1016\/j.oraloncology.2020.105042","article-title":"Reprint of \u201cSquamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u201d","volume":"113","author":"Machiels","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_4","unstructured":"Food and Drug Administration (2026, January 10). CISplatin Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/018057s083lbl.pdf."},{"key":"ref_5","unstructured":"National Comprehensive Cancer Network (2026, January 31). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Head and Neck Cancers. Version 1. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf."},{"key":"ref_6","first-page":"4470","article-title":"A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240)","volume":"43","author":"Curt","year":"1983","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","article-title":"Taxol: A novel investigational antimicrotubule agent","volume":"82","author":"Rowinsky","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","first-page":"2166","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis","volume":"6","author":"Huang","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e472460","DOI":"10.1200\/EDBK-25-472460","article-title":"Updates on Treatments and Management of Nasopharyngeal Carcinoma","volume":"45","author":"Chua","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e702","DOI":"10.1002\/mco2.702","article-title":"Head and neck cancer: Pathogenesis and targeted therapy","volume":"5","author":"Liu","year":"2024","journal-title":"MedComm"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4161\/cbt.9.5.10981","article-title":"Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck","volume":"9","author":"Rivero","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/030089160609200108","article-title":"Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx","volume":"92","author":"Fallai","year":"2006","journal-title":"Tumori J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/ccij.ccij_114_20","article-title":"Comparison of concurrent chemoradiation with daily gefitinib versus daily erlotinib in locally advanced oropharyngeal cancers","volume":"10","author":"Nagpal","year":"2021","journal-title":"Clin. Cancer Investig. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdw204","article-title":"Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer","volume":"27","author":"Argiris","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_16","first-page":"6","article-title":"Phase II\/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer","volume":"1","author":"Safwat","year":"2019","journal-title":"Gulf J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2005.07.010","article-title":"Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial","volume":"23","author":"Budach","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2014.12.034","article-title":"Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU\/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: Long-term results of the ARO 95-06 randomized phase III trial","volume":"91","author":"Budach","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jrr\/rrt054","article-title":"Randomized phase III trial of concurrent chemoradiotherapy vs. accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer","volume":"54","author":"Chitapanarux","year":"2013","journal-title":"J. Radiat. Res."},{"key":"ref_22","first-page":"165","article-title":"Concurrent chemoradiation in locally advanced head and neck cancers: A comparative study of weekly Paclitaxel versus Cisplatin-based regimen","volume":"22","author":"Essa","year":"2010","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_23","first-page":"85","article-title":"A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer","volume":"17","author":"Ezzat","year":"2005","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0360-3016(02)03792-6","article-title":"Locoregionally advanced carcinoma of the oropharynx: Conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy\u2014A multicenter randomized trial","volume":"55","author":"Olmi","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy with Cisplatin Versus Cetuximab in Patients with Locoregionally Advanced Head and Neck Squamous Cell Cancer","volume":"39","author":"Brun","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2017.76.2591","article-title":"Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial","volume":"36","author":"Geoffrois","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(14)71200-8","article-title":"Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): A randomised, controlled, open-label phase 2 trial","volume":"16","author":"Giralt","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12032-010-9811-x","article-title":"Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: A phase III study","volume":"29","author":"Halim","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): An open-label, multicentre, parallel-group, randomised, phase 2\/3 trial","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mercke, C., Wickart-Johansson, G., Sj\u00f6din, H., da Silva, P.F.N., von D\u00f6beln, G.A., Margolin, G., Jaraj, S.J., Carstens, H., Berglund, A., and Lax, I. (2023). Radiotherapy\u2014Dose Escalated for Large Volume Primary Tumors\u2014And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck\u2014A Randomized Phase II Trial. Cancers, 15.","DOI":"10.3390\/cancers15092543"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mds291","article-title":"Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: Results from a randomized, phase II prospective trial","volume":"24","author":"Rueda","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk hpv-associated oropharyngeal cancer (TROG 12.01)\u2014A trans-Tasman radiation oncology group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/030089161009600210","article-title":"Radiotherapy alone or with concomitant daily low-dose carboplatin in locally advanced, unresectable head and neck cancer: Definitive results of a phase III study with a follow-up period of up to ten years","volume":"96","author":"Redda","year":"2010","journal-title":"Tumori J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ijrobp.2005.10.039","article-title":"Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: Updated results of a randomized multicentric trial in advanced head-and-neck cancer","volume":"64","author":"Semrau","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2016.4510","article-title":"Effect of Standard Radiotherapy with Cisplatin vs. Accelerated Radiotherapy with Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial","volume":"3","author":"Siu","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2017.76.2518","article-title":"Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial","volume":"36","author":"Tao","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): A multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_41","unstructured":"Thompson, D.J., Slevin, N.J., Baines, H., Betts, G., Bolton, S., Evans, M., Garcez, K., Irlam, J.H., Lee, L., and Melillo, N. (2023, November 12). A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab. Available online: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-00921572\/full."},{"key":"ref_42","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) (2024, September 20). Methodology Checklist 2: Randomised Controlled Trials. Available online: https:\/\/www.sign.ac.uk."},{"key":"ref_43","unstructured":"Phillips, B., Ball, C., Sackett, D., Badenoch, D., Straus, S., Haynes, B., Dawes, M., and Howick, J. (2024, September 20). Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009). Available online: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref_45","unstructured":"Sydes, M., and Tierney, J. (2004). Spreadsheet for Extracting Summary Statistics to Perform Meta-Analyses of Published Time-To-Event Data (Version 3.0), MRC Clinical Trials Unit."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Stat. Med."},{"key":"ref_48","unstructured":"R Core Team (2024). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_49","unstructured":"Carlin, B.P., Hong, H., Shamliyan, T.A., Sainfort, F., and Kane, R.L. (2013). Case Study Comparing Bayesian and Frequentist Approaches for Multiple Treatment Comparisons; AHRQ Methods for Effective Health Care."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Heukelom, J., Hamming, O., Bartelink, H., Hoebers, F., Giralt, J., Herlestam, T., Verheij, M., Brekel, M.v.D., Vogel, W., and Slevin, N. (2013). Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-84"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2020.09.008","article-title":"Avelumab\u2013cetuximab\u2013radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)","volume":"141","author":"Tao","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"v454","DOI":"10.1093\/annonc\/mdz252.010","article-title":"Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH)","volume":"30","author":"Tao","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1200\/JCO.2018.36.15_suppl.6076","article-title":"Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH)","volume":"36","author":"Tao","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.oraloncology.2017.06.002","article-title":"Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials","volume":"71","author":"Tao","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1748-717X-7-57","article-title":"Radiochemoimmunotherapy with intensity-modulated concomitant boost: Interim analysis of the REACH trial","volume":"7","author":"Jensen","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hed.25359","article-title":"Randomized phase II\/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216","volume":"41","author":"Zhang","year":"2019","journal-title":"Head Neck"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"v382","DOI":"10.1093\/annonc\/mdx374.023","article-title":"Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A randomized controlled multi-centered trial","volume":"28","author":"He","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1200\/JCO.2018.36.15_suppl.6009","article-title":"A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)","volume":"36","author":"McBride","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/j.ijrobp.2022.07.1302","article-title":"CAMRESBRT: Randomized Phase II Trial of Camrelizumab with Stereotactic Body Radiotherapy vs. Camrelizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"114","author":"Lei","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_61","first-page":"9","article-title":"A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation with Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck","volume":"13","author":"Venkateshulu","year":"2021","journal-title":"Cureus J. Med. Sci."},{"key":"ref_62","first-page":"7","article-title":"Intensity modulated radiotherapy with cisplatin or cetuximab in patients undergoing chemoradiation for squamous cell carcinoma head and neck","volume":"15","author":"Venkateshulu","year":"2021","journal-title":"Onkol. Radioter."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0167-8140(20)30475-8","article-title":"PO-133 Concurrent Chemoradiation in Head and Neck Cancers Comparing Weekly Cisplatin vs. Oral Hydroxyurea","volume":"141","author":"Vias","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S593","DOI":"10.1016\/j.annonc.2023.09.2088","article-title":"944TiP Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and\/or metastatic head and neck squamous cell carcinoma: The IMPORTANCE trial","volume":"34","author":"Tamaskovics","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"TPS6091","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS6091","article-title":"TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer","volume":"39","author":"Bourhis","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1016\/j.ijrobp.2022.07.1372","article-title":"NANORAY-312: A Phase III Pivotal Study of NBTXR3 Activated by Investigator\u2019s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-Based Chemotherapy-Ineligible Elderly Patients with Locally Advanced HNSCC","volume":"114","author":"Yom","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ijrobp.2022.09.003","article-title":"Radiotherapy with Durvalumab vs. Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin: Phase II Results of NRG-HN004","volume":"114","author":"Mell","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.22.00980","article-title":"Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients with Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation","volume":"41","author":"Patil","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/jco.2009.27.15_suppl.6041","article-title":"A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer","volume":"27","author":"Krishnamurthyreddy","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.ijrobp.2012.07.394","article-title":"Cetuximab\/Radiation Therapy (CET + RT) Versus Concomitant Chemoradiation Therapy (cCHT + RT) with or Without Induction Docetaxel\/Cisplatin\/5Fluorouracil (TPF) in Locally Advanced Head-and-Neck Squamous Cell Carcinoma (LASCCHN)\u2014Preliminary Results on Toxicity of a Randomized, 2 \u00d7 2 Factorial, Phase II-III Study (NCT01086826)","volume":"84","author":"Ghi","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/jco.2010.28.15_suppl.5530","article-title":"An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study","volume":"28","author":"Babu","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_72","unstructured":"Liu, L. (2023, November 12). Clinical Study of PD-1 Inhibitors Combined with Concurrent Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous cell Carcinoma: A Prospective, Randomized, Paralle Controlled Study. Available online: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100046011."},{"key":"ref_73","unstructured":"(2023, November 12). EU Clinical Trials Register, Randomized Phase IV Trial to Compare Cetuximab with Concomitant Radiation Therapy with Concomitant Mitomycin-C and 5-FU with Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Available online: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-001296-20-AT."},{"key":"ref_74","unstructured":"(2023, November 12). EU Clinical Trials Register, Open Label Randomized Phase II, Multicentre, Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Concomitant-Boost Accelerated Radiotherapy Followed or Not by a Complementary Treatment with Cetuximab in Patients with Locally Advanced Oropharynx Squamous Cell Carcinoma. Available online: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01013216\/full."},{"key":"ref_75","unstructured":"(2023, November 12). EU Clinical Trials Register, A Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination with Radiotherapy in Patients with Advanced Cancer of the Head and Neck. Available online: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-002676-87-PL."},{"key":"ref_76","first-page":"333","article-title":"CheckMate 9TM: Phase 3 study of nivolumab + radiotherapy (RT) vs. cetuximab + RT in cisplatin-ineligible patients with intermediate-\/high-risk locally advanced squamous cell carcinoma of the head\/neck","volume":"6","author":"Haddad","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_77","unstructured":"(2023, November 12). Iranian Registry of Clinical Trials, Evaluation the Efficacy and Safety of Cetuximab Bio-Similar Compared to Erbitux in the Patients with Head and Neck Squamous Cell Carcinoma. Available online: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20190112042328N1."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1200\/JCO.2020.38.15_suppl.6574","article-title":"DURTRERAD: A phase II openlabel study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC-Results of the preplanned feasibility interim analysis","volume":"38","author":"Klinghammer","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_79","unstructured":"Skinner, H. (2023, November 12). Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) with Cetuximab +\/\u2212 Docetaxel Followed by Adjuvant Cetuximab +\/\u2212 Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN). Available online: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01013521\/full."},{"key":"ref_80","unstructured":"Wilke, C. (2023, November 12). A Randomized, Phase II Study of Definitive Radiotherapy with Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: An ERCC1 Biomarker Enrichment and Interaction Design. Available online: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01012918\/full."},{"key":"ref_81","unstructured":"Groupe Oncologie Radiotherapie Tete et Cou (2023, November 12). Randomized Trial of Avelumab-Cetuximab-Radiotherapy Versus SoCs in LA SCCHN (REACH), Available online: https:\/\/clinicaltrials.gov\/show\/NCT02999087."},{"key":"ref_82","unstructured":"Mell, L. (2023, November 12). Chemoradiation vs. Immunotherapy and Radiation for Head and Neck Cancer, Available online: https:\/\/clinicaltrials.gov\/show\/NCT03383094."},{"key":"ref_83","unstructured":"(2023, November 12). Institut Claudius Regaud, Cisplatin or ImmunoTHerapy in Association with Definitive Radiotherapy in HPV-Related Oropharyngeal Squamous Cell Carcinoma: A Randomized Phase II Trial, Available online: https:\/\/clinicaltrials.gov\/show\/NCT03623646."},{"key":"ref_84","unstructured":"Harari, P. (2023, November 12). Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-risk Head and Neck Cancer, Available online: https:\/\/clinicaltrials.gov\/show\/NCT04411121."},{"key":"ref_85","unstructured":"Johnson & Johnson Enterprise Innovation Inc. (2023, November 12). NBTXR3 With or Without Cetuximab in LA-HNSCC, Available online: https:\/\/clinicaltrials.gov\/show\/NCT04892173."},{"key":"ref_86","unstructured":"Sher, D. (2023, November 12). Combining Radiation Therapy with Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck, Available online: https:\/\/clinicaltrials.gov\/show\/NCT05721755."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"904341","DOI":"10.1155\/2014\/904341","article-title":"Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment","volume":"2014","author":"Hu","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hed.23609","article-title":"Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer","volume":"37","author":"Tang","year":"2015","journal-title":"Head Neck"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","article-title":"Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and\/or recurrent squamous cell carcinoma of the head and neck","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_91","first-page":"149","article-title":"Gemcitabine concurrent with radiation therapy for locally advanced head and neck carcinomas","volume":"8","author":"Chauhan","year":"2008","journal-title":"Afr. Health Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1200\/jco.2015.33.15_suppl.6036","article-title":"A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)","volume":"33","author":"Li","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"20160105","DOI":"10.1259\/bjr.20160105","article-title":"Cost analysis of cetuximab (Erbitux) plus radiotherapy (ERT) versus concomitant cisplatin plus radiotherapy (CRT) within an NHS oncology unit (single institution): A pilot study","volume":"89","author":"Caroline","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00066-014-0626-0","article-title":"Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas","volume":"190","author":"Levy","year":"2014","journal-title":"Strahlenther. Onkol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4172\/1948-5956.1000082","article-title":"Low dose weekly paclitaxel versus low dose weekly cisplatin with concomitant radiation in locally advanced head and neck cancers","volume":"3","author":"Hamed","year":"2011","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/0019-509X.48596","article-title":"A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers","volume":"46","author":"Jain","year":"2009","journal-title":"Indian J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/annonc\/mdq736","article-title":"A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers","volume":"22","author":"Salama","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1470-2045(09)70306-7","article-title":"Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial","volume":"11","author":"Tobias","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.2011.35.9315","article-title":"Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial","volume":"30","author":"Janssens","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/jco.2012.30.15_suppl.5513","article-title":"Cetuximab\/radiotherapy (CET + RT) versus concomitant chemoradiotherapy (cCHT + RT) with or without induction docetaxel\/cisplatin\/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2 \u00d7 2 factorial, phase II-III study (NCT01086826)","volume":"30","author":"Ghi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"111033","DOI":"10.1016\/j.radonc.2025.111033","article-title":"Non-cisplatin concurrent agents plus definitive radiotherapy for locally advanced head and neck cancer: A network meta-analysis of randomized studies","volume":"210","author":"Petrelli","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-Effect vs. Random-Effects Models for Meta-Analysis: 3 Points to Consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Glob. Spine J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000371821","article-title":"Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin Appendage Disord."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4976032","DOI":"10.1155\/2022\/4976032","article-title":"Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis","volume":"2022","author":"Tian","year":"2022","journal-title":"J. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2018.03.001","article-title":"Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options","volume":"80","author":"Iocca","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Gupta, T., Kannan, S., Ghosh-Laskar, S., and Agarwal, J.P. (2018). Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and\/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200137"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/biom.13342","article-title":"Testing small study effects in multivariate meta-analysis","volume":"76","author":"Hong","year":"2020","journal-title":"Biometrics"}],"updated-by":[{"DOI":"10.3390\/cancers18213466","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:00:00Z","timestamp":1793059200000}}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:37:57Z","timestamp":1793104677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":109,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101599"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101599","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}